FAIR VALUE REPORT
3M · MMM · OCT 20, 2026 · AFTER RESULTS OF OCT 20, 2026
Is 3M's 4.8% cash yield real, or a gap in the PFAS payment calendar?
3M beats on adjusted earnings every quarter and buys back billions, yet the shares trail the S&P 500 by 11 points in 2026 and sit 27.9% above the model's $116.79. The difference is cash that has not left the building yet.
FPI VERDICT · OCT 20, 2026
DCF 50% · RELATIVE 30% · CONSENSUS 20%
27.9%
above fair value
UNCERTAINTY
LOW ±10%
FAIR VALUE BAND
$105.11 – $128.47
PRICE VS BAND
ABOVE THE BAND
Numbers as of publication. Today's fair value and price: MMM stock page → · How uncertainty is rated →
5 MIN READ
THE REPORT IN 3 POINTS
- 013M trades at $162.00, 27.9% above the FPI fair value of $116.79, and 27.9x earnings versus a peer median of 15.6x.
- 022025 adjusted free cash flow was $4.4 billion but operating cash flow only $2.3 billion, the gap being PFAS and earplug payments.
- 03PFAS water payments drop to $0.4 billion in 2026 then jump to $2.6 billion in 2027, with 2027 guidance due January 2027.
A $2.39 bar, a 24.9% margin and a 1.7% drop into the print
3M ($MMM) went into its 20 October 2026 release with the shares at $162.00, down 1.7% on 19 October, the session before the numbers. Wall Street was looking for adjusted earnings of $2.39 a share on revenue of $6.61 billion, against $2.19 and adjusted sales of $6.3 billion in the quarter to September 2025. The June quarter set the bar, when 3M posted 5.4% organic growth, a record 24.9% adjusted operating margin and adjusted EPS of $2.40 and lifted its 2026 adjusted EPS range to $8.80-8.95 from $8.50-8.70.
3M has topped the consensus in four straight quarters by 1.7% to 8.1%, and the shares still moved -7.0% after the January 2026 print and +7.3% after the July one. The net result for 2026 is a share price up 1.2% against 12.3% for the S&P 500, 11.8% below the 52-week high of $184.90. The market pays 27.9x reported earnings for a turnaround it does not fully trust, and the doubt sits in one line of the cash flow statement.
| REPORTED | REVENUE | VS EST. | EPS | VS EST. | PRICE REACTION |
|---|---|---|---|---|---|
| JUL 21, 2026 | $6.5B | +1.6% | $2.40 | +6.7% | +7.3% |
| APR 21, 2026 | $6.0B | −0.1% | $2.14 | +8.1% | −1.9% |
| JAN 20, 2026 | $6.0B | −0.1% | $1.83 | +1.7% | −7.0% |
| OCT 21, 2025 | $6.5B | +4.3% | $2.19 | +5.8% | +7.7% |
| JUL 18, 2025 | $6.3B | +3.7% | $2.16 | +7.5% | −3.7% |
| APR 22, 2025 | $6.0B | +3.4% | $1.88 | +5.6% | +7.9% |
| JAN 21, 2025 | $6.0B | +3.9% | $1.68 | +0.6% | +5.7% |
| OCT 22, 2024 | $6.3B | +3.9% | $1.98 | +3.7% | −5.1% |
3M beat the EPS estimate in 8 of the last 8 quarters. Price reaction is the move on the trading day after the results.
$4.4 billion of "adjusted" cash in 2025, $2.3 billion that actually arrived
For full-year 2025 3M reported adjusted free cash flow of $4.4 billion but operating cash flow of just $2.3 billion. The $2.1 billion difference is mostly the lawyers: the adjustment strips out payments for PFAS and the Combat Arms earplug settlements. GAAP EPS for 2025 was $6.00, down 17%, while adjusted EPS was $8.06, up 10%. Free cash flow is what is left after the bills; here the biggest bill is being set aside.
Under the public water systems settlement 3M pays $10.5-12.5 billion between 2024 and 2036, and the pre-tax schedule runs $1.8 billion in 2025, $0.4 billion in 2026, $2.6 billion in 2027 and $1.6 billion in 2028. On top sits the $6.0 billion earplug programme running to 2029 and a New Jersey deal, approved by a federal court on 7 August 2026, of $275-325 million through 2034. So 2026 is the light year. The 10-Q for the quarter to June 2026 shows first-half operating cash flow of $1.6 billion, up $2.6 billion on the first half of 2025, primarily because PFAS and earplug payments were lower and insurance recoveries came in.
In that light year 3M bought back $4.8 billion of stock, 5.8% of its market value, and in the quarter to March 2026 alone it returned $2.4 billion to shareholders while generating $0.6 billion of operating cash. The cushion is the roughly 15% stake in Solventum, worth $2.0 billion at 30 June 2026, which 3M intends to sell within five years of the 2024 spin-off. That covers most of the 2027 instalment once, not the 2028 one.
Why the model stops at $116.79 - 27.9% below the price
The FPI fair value is $116.79, which puts the $162.00 share price 27.9% above it. Half of the model is a discounted cash flow, and 3M gives a DCF plenty to like: a 14.6% return on invested capital, an 11.9% net margin and a 4.77% free cash flow yield, all well above the conglomerate medians of 3.5%, 5.5% and 2.09%. But a DCF counts every dollar that leaves, so the 2027-2029 settlement outflows sit in the early years where they weigh most, and a 3-year revenue CAGR of -10.0% after the Solventum spin gives it no growth base to lean on.
The peer leg, 30% of the model, is harsher still. 3M trades at 27.9x earnings and 17.1x EV/EBITDA against a conglomerate median of 15.6x and 10.8x and an industrials median of 23.7x and 12.9x. Illinois Tool Works, the closest match by size at $77.55 billion, earns a 19.4% net margin and a 24.7% ROIC yet trades at 24.1x, so 3M is dearer on lower returns. 3M itself changed hands at 9.9x earnings at the end of 2022 and 14.7x at the end of 2021; the multiple has nearly tripled while revenue shrank. The consensus leg, 20% of the weight, is the only one anchored near $191.
Over the 120 days to October 20, 2026 the share price went from $162.53 to $162.00 (−0.3%) and the FPI fair value from $112.39 to $116.79 (+3.9%). The gap moved from 30.9% above fair value to 27.9% above.
Street vs model: $191 against $116.79, a 64% gap
Of 33 analysts, 16 say buy, 16 hold and 1 sell, and the price targets run from $171 to $218 with a median of $191. That median is 17.9% above the share price and 63.5% above the fair value. The direction is down: targets issued in the quarter to 6 October 2026 average $183.50, JPMorgan cut to $185 from $205 on 9 October 2026, and Mizuho set $180 on 23 July 2026. The one target below the price vanished on 25 September 2026, when Bernstein moved from Underperform to Market Perform and from $145 to $171.
A $191 target is roughly 21.5x the midpoint of the $8.80-8.95 adjusted EPS guide, a multiple that treats the litigation payments as already paid. The model's two larger legs rest on cash after litigation and a peer multiple nearer 16x reported earnings. Insiders are not arguing with the model: 78 sales worth $21.0 million and no purchases in 12 months, including the Chief Legal Officer selling 7,669 shares at $171.20 on 22 July 2026.
16 buy · 16 hold · 1 sell. FPI fair value sits 32% below the lowest Street target, the share price is below the whole range.
Four numbers to watch: $160.72, $2.6 billion, 25% and $116.79
For the shares to re-rate towards the Street's $191, the adjusted operating margin has to hold at or above 25% through 2027 while organic growth stays above the 3.5% the company guided for 2026, and a Solventum stake sale would need to pre-fund the $2.6 billion 2027 water instalment so buybacks do not stop when the bill arrives. For a re-rating down, the trigger is the 2027 cash guidance due in January 2027: the 2027 step-up of $2.2 billion in water payments alone exceeds the $1.6 billion of operating cash flow the whole first half of 2026 produced.
The levels to watch:
- $160.72, the 200-day average, just $1.28 below the price; a close beneath it leaves the 52-week low of $139.34 as the next marker.
- $2.6 billion, the 2027 PWS instalment, against whatever operating cash flow the 10-K for 2026 shows in February 2027.
- 25%, the adjusted operating margin line; the 2026 guide of 0.7-0.8 percentage points of expansion on 2025's 23.4% implies a year just above 24%, so a quarter below 24% means June's 24.9% was the top.
- $116.79, the fair value; the model's verdict flips only below that level, which is 27.9% away.
HIGHEST WALL STREET TARGET
- 01UBS set the high target of $218 on 22 July 2026, a multiple that works only if the 24.9% record adjusted operating margin from the June 2026 quarter holds.
- 02A Solventum stake worth $2.0 billion at 30 June 2026 could pre-fund the $2.6 billion 2027 water instalment and keep buybacks running after 2026's $4.8 billion.
- 033M earns a 14.6% ROIC and 11.9% net margin against conglomerate medians of 3.5% and 5.5%, and has beaten consensus four quarters running by 1.7% to 8.1%.
BOTTOM OF THE FPI FAIR VALUE BAND
- 01The 2027 PFAS water instalment of $2.6 billion exceeds the $1.6 billion of operating cash flow produced in the whole first half of 2026.
- 022025 adjusted free cash flow of $4.4 billion came with operating cash flow of just $2.3 billion, a $2.1 billion gap that is mostly litigation payments.
- 03At 27.9x earnings and 17.1x EV/EBITDA against conglomerate medians of 15.6x and 10.8x, the multiple has nearly tripled from 9.9x at the end of 2022 while revenue fell at a 10.0% three-year CAGR.
FPI FAIR VALUE $116.79 · FPI fair value of $116.79 sits near the bear anchor of $105.11 and far below the $218.00 bull case, because the 2027-2029 settlement outflows land in the DCF years that matter most.
FPI fair value blends a discounted cash flow model (50%), relative valuation against sector peers (30%) and analyst consensus (20%), updated daily. How the model works →
TRACK THE NUMBER
Get notified when MMM's fair value changes
Set your own buy price for MMM and the app alerts you when the stock reaches it. iOS and Android.
MORE MMM REPORTS
This is the first FPI fair value report on 3M. The next one follows the company's next quarterly results.
MORE REPORTS IN INDUSTRIALS
- PLUG · Plug's $99 million profit came from its own falling shares - so what does $1.35 buy?NOV 12, 2026
- BA · Can a cash promise for 2028 hold Boeing at $167 today?OCT 29, 2026
- WM · WM rose 14% in a month on a rival's earnings. Is $236 still worth paying?OCT 28, 2026
- LMT · Is $590 for Lockheed paying for the missiles, or for an F-35 contract nobody has signed?OCT 23, 2026
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.





